Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PharmaCorp RxTSXV:PCRX 35 EV-to-FCF is -26.35 as of Jul. 31, 2026. GuruFocus rates TSXV:PCRX with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 406 Healthcare Providers & Services companies, PharmaCorp Rx ranks worse than 246305.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PharmaCorp Rx's Enterprise Value is C$79.84 Mil.
PharmaCorp Rx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was C$-3.03 Mil. Therefore, PharmaCorp Rx's EV-to-FCF for today is -26.35.
The historical rank and industry rank for PharmaCorp Rx's EV-to-FCF or its related term are showing as below:
TSXV:PCRX'
s EV-to-FCF Range Over the Past 10 Years
Min: -292.84 Med: -22.96 Max: 448.11
Current: -25.7
During the past 5 years, the highest EV-to-FCF of PharmaCorp Rx was 448.11. The lowest was -292.84. And the median was -22.96.
TSXV:PCRX's EV-to-FCF is ranked worse than 100% of 406
companies
in the Healthcare Providers & Services industry
Industry Median: 17.83
vs TSXV:PCRX: -25.70
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PharmaCorp Rx's PE Ratio (TTM) for today is calculated as:
PharmaCorp Rx's share price for today is C$0.50.
PharmaCorp Rx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
PharmaCorp Rx EV-to-FCF Related Terms
PharmaCorp Rx EV-to-FCF Historical Data
* Premium members only.
The historical data trend for PharmaCorp Rx's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, PharmaCorp Rx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCorp Rx EV-to-FCF vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmaCorp Rx's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PharmaCorp Rx's EV-to-FCF falls into.
PharmaCorp Rx's current Enterprise Value is C$79.84 Mil.
PharmaCorp Rx's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-3.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCorp Rx (TSXV:PCRX) has a EV-to-FCF of -26.35 as of Jul. 31, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PharmaCorp Rx and its competitors. According to the industry distribution chart, PharmaCorp Rx ranks #999999 out of 406 companies in the Healthcare Providers & Services industry.
Is PharmaCorp Rx's EV-to-FCF too high?
PharmaCorp Rx's current EV-to-FCF is -26.35. Based on the distribution chart, PharmaCorp Rx ranks #999999 out of 406 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmaCorp Rx has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCorp Rx's EV-to-FCF compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, PharmaCorp Rx ranks #999999 out of 406 companies for EV-to-FCF. This places PharmaCorp Rx in the lower half of its industry. The industry median EV-to-FCF is 17.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Healthcare Providers & Services company?
The median EV-to-FCF among Healthcare Providers & Services companies is 17.83, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PharmaCorp Rx and its competitors. For the Healthcare Providers & Services industry, the median EV-to-FCF is 17.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCorp Rx's current EV-to-FCF is -26.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCorp Rx stock overvalued right now?
PharmaCorp Rx (TSXV:PCRX) has a current EV-to-FCF of -26.35. The current EV-to-FCF is -26.35. PharmaCorp Rx's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PharmaCorp Rx (TSXV:PCRX), the current EV-to-FCF is -26.35 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCorp Rx Inc operates three PharmaChoice bannered pharmacies in Canada and will continue to acquire PharmaChoice Canada-branded pharmacies as it come to market in conjunction with its strategic alliance agreement with PharmaChoice Canada. The company will also acquire independently owned non-PharmaChoice Canada-bannered pharmacies in Canada, and thereafter, continue to operate such acquired pharmacies under a PharmaChoice Canada banner.
35GF Score
Get the complete analysis for TSXV:PCRX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:PCRX has been successfully added to your 
